Oxidative stress, inflammation and cardiovascular mortality in haemodialysis -: role of seniority and intravenous ferrotherapy:: analysis at 4 years of follow-up

被引:51
作者
Bayés, B
Pastor, MC
Bonal, J
Foraster, A
Romero, R
机构
[1] Hosp Badalona Germans Trias & Pujol, Dept Nephrol, Badalona 08916, Spain
[2] Hosp Badalona Germans Trias & Pujol, Dept Clin Biochem, Badalona 08916, Spain
[3] Hosp Badalona Germans Trias & Pujol, Haemodialysis Unit, Badalona 08916, Spain
关键词
C-reactive protein; cardiovascular mortality; haemodialysis; oxidative stress;
D O I
10.1093/ndt/gfi294
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Cardiovascular disease is the principal cause of morbidity and mortality in haemodialysis patients. The classic risk factors do not account for all cases of elevated cardiovascular disease in this patient population and it is becoming increasingly clear that other cardiovascular risk factors are implicated. The objective of this study was to analyse whether or not C-reactive protein (CRP) and plasma copper oxidized anti-lipoprotein (oxLDL) antibody titre are risk factors for cardiovascular mortality during 4 years of follow-up. Methods. A prospective follow-up study was carried out in 94 stable, chronic haemodialysis patients for 48 months (July 1999-July 2003) (gender: 50 males and 44 females; mean age: 67 +/- 14 years). Eighty-four per cent of these patients were receiving intravenous erythropoietin and 63% were receiving intravenous ferrotherapy (iron gluconate). Basal markers of inflammation and oxidative stress were determined at the beginning of the study. CRP levels were determined by chemiluminescent enzyme-labelled immunometric assay. The oxLDL antibody titre was measured by enzyme-linked immunosorbent assay using native LDL and oxLDL as antigens. Results. Fifty deaths occurred during the study, 66% (n = 33) of which were due to cardiovascular disease. Patients presented with basal CRP and oxLDL levels indicative of chronic inflammation and elevated oxidative stress [CRP median: 5.16 mg/l (25-75% percentile: 0.35-88.7 mg/l); oxLDL antibodies median: 153 (optical density at 495 nm x 1000) (25-75% percentile: 112-214)]. A positive correlation was found between CRP and age (r = 0.33, P = 0.003). Study of the risk factors demonstrated that age (P = 0.007), oxLDL antibody titre (P = 0.04) and albumin (P = 0.02) were the only predictors of cardiovascular mortality at 4 years of follow-up in this patient population. The Cox proportional hazards model for cardiovascular mortality showed that of the markers studied, oxLDL antibody titre was an independent risk factor for cardiovascular mortality. Conclusions. Oxidative stress (oxLDL antibody titre) is one of the principal risk factors for cardiovascular mortality in this population of haemodialysis patients. Intravenous ferrotherapy, due to its pro-oxidant properties, probably favours oxidative stress. Serum concentration of CRP was not a good predictive factor of cardiovascular mortality during 4 years of follow-up, possibly because of the slight positive correlation that exists between CRP and age.
引用
收藏
页码:984 / 990
页数:7
相关论文
共 18 条
[1]   Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients [J].
Bayés, B ;
Pastor, MC ;
Bonal, J ;
Juncà, J ;
Hernandez, JM ;
Riutort, N ;
Foraster, A ;
Romero, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (01) :106-112
[2]   Homocysteine and lipid peroxidation in haemodialysis:: role of folinic acid and vitamin E [J].
Bayés, B ;
Pastor, MC ;
Bonal, J ;
Juncà, J ;
Romero, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (11) :2172-2175
[3]   Role of oxidized low-density lipoprotein in the atherosclerosis of uremia [J].
Drüeke, TB ;
Khoa, TN ;
Massy, ZA ;
Witko-Sarsat, V ;
Lacour, B ;
Descamps-Latscha, B .
KIDNEY INTERNATIONAL, 2001, 59 :S114-S119
[4]   The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia [J].
Himmelfarb, J ;
Stenvinkel, P ;
Ikizler, TA ;
Hakim, RM .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1524-1538
[5]   Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease [J].
Holvoet, P ;
Mertens, A ;
Verhamme, P ;
Bogaerts, K ;
Beyens, G ;
Verhaeghe, R ;
Collen, D ;
Muls, E ;
Van de Werf, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (05) :844-848
[6]   Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy [J].
Lim, PS ;
Wei, YH ;
Yu, YL ;
Kho, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (11) :2680-2687
[7]   Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE study [J].
Longenecker, JC ;
Coresh, J ;
Powe, NR ;
Levey, AS ;
Fink, NE ;
Martin, A ;
Klag, MJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (07) :1918-1927
[8]   ENHANCED LDL OXIDATION IN UREMIC PATIENTS - AN ADDITIONAL MECHANISM FOR ACCELERATED ATHEROSCLEROSIS [J].
MAGGI, E ;
BELLAZZI, R ;
FALASCHI, F ;
FRATTONI, A ;
PERANI, G ;
FINARDI, G ;
GAZO, A ;
NAI, M ;
ROMANINI, D ;
BELLOMO, G .
KIDNEY INTERNATIONAL, 1994, 45 (03) :876-883
[9]   Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association [J].
Pearson, TA ;
Mensah, GA ;
Alexander, RW ;
Anderson, JL ;
Cannon, RO ;
Criqui, M ;
Fadl, YY ;
Fortmann, SP ;
Hong, Y ;
Myers, GL ;
Rifai, N ;
Smith, SC ;
Taubert, K ;
Tracy, RP ;
Vinicor, F .
CIRCULATION, 2003, 107 (03) :499-511
[10]   Cardiac effects of chronic inflammation in dialysis patients [J].
Santoro, A ;
Mancini, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :10-15